Other cationic molecules with antibiotic and anti-inflammatory potential, such as lysozyme, lactoferrin, secretory leukocyte protease inhibitor (SLPI), and elafin, may also be of interest for therapeutic development in CF. This evidence concerns the gene LYZ and cystic fibrosis.